Drugs / PC786
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03236233 | Jun → Dec 2017 | respiratory syncytial virus infectious disease | Pulmocide Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03382431 | Nov 2017 → May 2018 | respiratory syncytial virus infectious disease | Pulmocide Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03715023 | Nov 2018 → Feb 2019 | respiratory syncytial virus infectious disease | Pulmocide Ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PC786 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03715023 ↗ |
| Action | Inhibit | “PC786 is a nebulized nonnucleoside respiratory syncytial virus (RSV) polymerase inhibitor designed to treat RSV” PMID 33216113 ↗ Jun 2022 |
| Modality | Small molecule | “PC786 is a nebulized nonnucleoside respiratory syncytial virus (RSV) polymerase inhibitor” PMID 33216113 ↗ Jun 2022 |
| Route | Inhaled | “Inhaled Doses of PC786” NCT03236233 ↗ |